Inhibrx (NASDAQ:INBX – Get Free Report) announced its earnings results on Monday. The company reported ($3.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21), Zacks reports. The firm had revenue of $0.10 million for the quarter.
Inhibrx Trading Down 1.1 %
Shares of Inhibrx stock opened at $13.94 on Tuesday. Inhibrx has a 12-month low of $10.80 and a 12-month high of $35.42. The firm’s 50-day moving average price is $13.33 and its two-hundred day moving average price is $14.67.
Analyst Ratings Changes
Separately, JMP Securities reissued a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.
Inhibrx Company Profile
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Stories
- Five stocks we like better than Inhibrx
- EV Stocks and How to Profit from Them
- Southwest Airlines Could Triple From Here—Here’s How
- 3 Fintech Stocks With Good 2021 Prospects
- Salesforce: An Early AI Opportunity With Long-Term Potential
- What is the S&P 500 and How It is Distinct from Other Indexes
- Taiwan Semiconductor Valuation: How Realistic Is the Price?
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
